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Objectives: Maternal obesity imposes significant health risks in the offspring including diabetes 
and dyslipidemia. We previously showed that the hypoglycaemic agent exendin-4 (Ex-4) 
administered from weaning can reverse the maternal impact of ‘transmitted disorders’ in such 
offspring. However daily injection for six-weeks was required and the beneficial effect lapsed upon 
drug withdrawal. This study aimed to investigate whether short term Ex-4 treatment during suckling 
in a rodent model can reverse transmitted metabolic disorders due to maternal obesity. 
Methods: Maternal obesity was induced in female Sprague Dawley rats by high-fat diet feeding for 
6 weeks, throughout gestation and lactation. Female offspring were treated with Ex-4 (5μg/kg/day) 
between postnatal day (P) 4 and 14. Female offspring were harvested at weaning (P20). Lipid and 
glucose metabolic markers were measured in the liver and fat. Appetite regulators were measured in 
the plasma and hypothalamus. 
Results: Maternal obesity significantly increased body weight, fat mass, and liver weight in the 
offspring. There was an associated inhibition of peroxisomal proliferator activated receptor gamma 
coactivator 1α (PGC1α), increased fatty acid synthase (FASN) expression in the liver, and reduced 
adipocyte triglyceride lipase (ATGL) expression. It also increased the plasma gut hormone ghrelin 
and reduced glucagon-like peptide-1. Ex-4 treatment partially reversed the maternal impact on 
adiposity and impaired lipid metabolism in the offspring, with increased liver PGC1α and inhibition 
of FASN mRNA expression. Ex-4 treatment also increased the expression of a novel fat depletion 
gene a2-zinc-glycoprotein 1 in the fat tissue. 
Conclusion: Short term Ex-4 treatment during the suckling period significantly improved the 
metabolic profile in the offspring from the obese mothers at weaning. Long-term studies are needed 
to follow such offspring to adulthood to examine the sustained effects of Ex-4 in preventing the 
development of metabolic disease. 
 




The global obesity epidemic is associated with a dramatic rise in the rate of childhood obesity. 
Epidemiological and animal studies have established that maternal obesity plays a significant role in 
the increased incidence of childhood obesity and the future risk of obesity and obesity related 
chronic diseases, including diabetes and cardiovascular disorders (Bayol et al., 2005; Samuelsson et 
al., 2007; Chen & Morris, 2009; Bayol et al., 2010).  
 
The hypothalamic neuronal systems that regulate appetite and energy homeostasis are not mature in 
newborn rats, with development continuing until weaning (Pinto et al., 2004; Bouret & Simerly, 
2006). Specifically between postnatal days (P) 4–14, there is a marked increase in serum levels of 
the hormone leptin (called the ‘leptin surge’). This is believed to support the post-natal development 
and maturation of hypothalamic neuronal projections between nuclei involved in the regulation of 
energy homeostasis (Ahima et al., 1998; Bouret et al., 2004). Leptin binds to its active form of the 
receptor Ob-Rb, followed by a phosphorylation of its downstream signal transducer and activator of 
transcription (STAT)3 leading to nuclear gene transcription. Any homeostatic disturbances during 
the ‘leptin surge’ period can alter the neural development resulting in metabolic disorders (e.g., 
obesity, hyperlipidemia), as observed in leptin-deficient ob/ob mice or pups of obese dams with an 
abnormally high level of blood leptin (Pinto et al., 2004; Yura et al., 2005; Bouret & Simerly, 2006; 
Kirk et al., 2009). We have shown that maternal obesity prior to gestation changes the 
hypothalamic appetite stimulator neuropeptide Y (NPY) expression (Chen et al., 2008), and impairs 
NPY production in response to both hypo- and hyperglycaemia (Chen & Morris, 2009; Chen et al., 
2014a). Dysregulation of NPY production is closely linked to hyperphagia during the suckling 
period and obesity at weaning in such offspring (Chen & Morris, 2009). Additional nutrient influx 
during the suckling period exacerbates metabolic disorders (Chen et al., 2008; Chen et al., 2009), 
which can subsequently impact on the second generation (Rajia et al., 2010). The replenishment of 
blood leptin in ob/ob mice during the time of the leptin surge induces synaptic reorganization and 
may reverse their abnormal phenotype (Pinto et al., 2004). This suggests that an intervention during 
the suckling period, especially during the leptin surge period, may reduce obesity and metabolic 
derangements in the offspring. The obese phenotype in pups from obese rats has been believed to be 
partially due to the composition of breast milk (Gorski et al., 2006) as the birth weight of pups from 
lean and obese dams are similar. However, nutritional approaches that use breast milk from lean 
rats have been  shown to be ineffective in changing the obese phenotype in offspring of obese 




We have previously used the hypoglycaemic drug exendin-4 (Ex-4), a glucagon-like peptide-1 
(GLP-1) receptor analogue, to treat offspring of obese dams for 6 weeks starting at weaning and 
have shown a reversal of the maternal impact on the propensity of the offspring to high-fat diet 
(HFD)-induced obesity (Chen et al., 2014b). However, such treatment needs to be administered 
daily and requires 6 weeks to exert significant effects to normalize glucose homeostasis. In a 
previous study, Ex-4 was injected daily into neonate rats with intrauterine growth restriction (IUGR) 
from P0-6 (Stoffers et al., 2003). Such short term Ex-4 treatment in early life permanently reversed 
the diabetic phenotype in the IUGR rats, via promoting the development of the pancreas, in 
particular insulin generating β-cells (Stoffers et al., 2003). Since maternal obesity causes insulin 
resistance at a very young age lasting until adulthood (Chen et al., 2008; Chen et al., 2009), we 
propose that short-term Ex-4 treatment during the early postnatal period may improve the metabolic 
profile in such offspring.  
 
We have recently demonstrated this in post-weaning rats (Chen et al., 2014b), but through 
mechanisms that are independent of pancreatic function. Since early postnatal neural development 
plays a critical role in determining the future risk of lipid and glucose metabolic disorders, we 
hypothesized that short-term Ex-4 treatment during P4-14 (leptin surge period) could improve the 
metabolic profile at weaning in the offspring of obese mothers. In this study we treated female rat 
pups with daily Ex-4 between P4 and P14, and measured body weight, adiposity, blood lipid levels 
and hypothalamic expression of regulators for energy homeostasis. In addition, we also measured 
mRNA expression of lipid and glucose metabolic regulators, such as adipose triglyceride lipase 
(ATGL), lipid oxidative regulator carnitine palmitoyltransferase-1 (CPT-1), peroxisome proliferator 
activated receptor gamma coactivator 1-alpha (PGC-1α) and its downstream signaling pathway, as 
well as the novel ‘fat depletion gene’ α(2)-zinc-glycoprotein 1 (AZGP1), in the fat and the liver.  
 
Animal and methods 
1. Modeling maternal obesity and treatment 
The study was approved by the Animal Care and Ethics Committees of University of New South 
Wales and University of Technology Sydney. Maternal obesity was modeled as previously 
described (Chen et al., 2012; Chen et al., 2014b). Briefly, female Sprague Dawley breeders (8 
weeks, Animal Resource Centre Pty. Ltd, WA, Australia) were housed under the standard 
conditions (Chen et al., 2012; Chen et al., 2014b). Maternal obesity was induced by consuming a 
pellet high-fat diet (HFD, 20kJ/g, 43.5% calorie as fat, SF03-020, Specialty Feeds, WA, Australia, 
n=8) for 6 weeks (Chen et al., 2014b), while the control rats were fed standard chow (11kJ/g, 14% 
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calorie as fat, Gordon’s specialty Stockfeeds, New South Wales, Australia, n=8). Then females 
were mated with lean male rats (8 weeks) from the same source. Litter size was adjusted to 10/litter 
(sex ~1:1). The same control or HFD diet was continued in the dams until the pups reached P20.  
  
From P4-14, 2-3 female pups from every litter were injected with saline daily to act as the control 
group (CS: chow offspring + saline, HS: HFD offspring + saline), while the other females were 
injected with Ex-4 (5μg/kg/day i.p., Auspep, VIC, Australia. CE: chow offspring + Ex-4, HE: HFD 
offspring + Ex-4).  
 
2. Leptin sensitivity test 
In a sub-cohort of offspring, leptin (15 μg/g, i.p., Sigma-Aldrich Pty Ltd, NSW, Australia) was 
injected into P10 pups (n=3-4, 1 per litter), with saline-injected into littermates to act as the control 
group as previously described (Kirk et al., 2009; Glavas et al., 2010). The whole hypothalamus was 
then harvested 45 min post-injection for the measurement of the protein levels of the downstream 
signaling of the leptin receptor, including STAT3 and its phosphorylated form p-STAT3 by western 
blotting. Blood glucose level was measured using a glucose meter (Accu-Chek®, Roche, Nutley, 
NJ) in saline treated pups before harvesting the brain.  
 
3. Sample collection 
At weaning (P20), female offspring were deeply anesthetised with sodium thiopental (Pentothal®, 
0.1mg/g, i.p, Abbott Australasia, NSW, Australia), immediately after being taken away from their 
mothers. Body weight and naso-annual length were measured prior to the blood collection by 
cardiac puncture, and blood glucose levels were measured using a glucose meter (Accu-Chek®, 
Roche, Nutley, NJ).  Serum was immediately separated by centrifugation at 4ºC (12,000g, 8 
minutes) and stored at -20°C in DNAse and RNAse free Eppendorf tubes for later measurement of 
hormones (ghrelin, GLP-1 and leptin) and lipids (triglyceride and non-esterified fatty acid). Pups 
were then killed by decapitation and the liver and fat pads (retroperitoneal, mesenteric fat and 
gonadal fat) were weighed. The hypothalamus was micro-dissected into regions containing arcuate 
nucleus (ARC) and paraventricular nucleus (PVN) as previously described (Chen et al., 2009). The 
brain, liver and retroperitoneal fat were then snap-frozen for mRNA measurement.  
 
4. Plasma lipid and hormone assays 
Liver lysis (n=8) was homogenized using chloroform:methanol mixture (2:1), and air-evaporated. 
Absolute ethanol (250μl) was used to dissolve the sample, which was used for triglyceride assay 
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(Chen et al., 2014b). Plasma or liver extracts, and glycerol standards (Sigma-Aldrich, Saint Louis, 
MO, USA) were incubated with triglyceride reagent (Roche Diagnostics, NJ, USA) to measure 
triglyceride concentration as previously described (Chen et al., 2014b). Plasma non-esterified free 
fatty acids (NEFA) were measured using a NEFA kit according to the manufacture’s instruction 
(WAKO, Osaka, Japan) (Chen et al., 2014b). Insulin levels were measured using an enzyme-linked 
immunosorbent assay (Crystal Chem, Downers Grove, IL, USA). Non-fasting plasma ghrelin, GLP-
1, and leptin levels were measured using Bio-Plex ProTM Assays kit (Bio-Rad Laboratories, Inc., 
Hercules, CA, USA) and Bio-Plex system® and Bio-Plex ManagerTM  (Chen et al., 2014b). 
 
5. Quantitative real-time PCR 
Tissue RNA (n=6-8) was extracted using TRIzol reagent (Sigma-Aldrich Pty Ltd, NSW, Australia), 
and cDNA synthesized as previously described (Chen et al., 2014b). Pre-optimised TaqMan 
probe/primers were used to measure the specific mRNA expression in the hypothalamus, liver and 
fat using real-time PCR (Eppendorf Realplex 2, Eppendorf AG, Hamburg, Germany). In the 
retroperitoneal fat, mRNA expression of the essential fatty acid and glucose metabolic markers, 
including PGC-1α and its downstream gluconeogenesis marker Forkhead box protein O (FOXO)1, 
fatty acid oxidative and lipid synthesis markers (peroxisome proliferator-activated receptor gamma 
(PPAR-γ), sterol regulatory element binding protein (SREBP)1c, CPT-1, and fatty acid synthase 
(FASN)) were measured in liver. CPT-1, lipase ATGL, and the ‘fat depletion gene’ AZGP1 were 
measured. Appetite regulators, including orexigenic NPY and Agouti-related protein (AGRP) and 
anorexigenic proopiomelanocortin (POMC), as well as active leptin receptor (OB-Rb) were 
measured in the ARC; while their downstream receptor neuropeptide Y1 receptor (NPY Y1R) and 
melanocortin 4 receptor (MC4R) and suppressor of cytokine signaling-3 (SOCS3) were measured 
in the PVN and ARC respectively. The probe sequences for all the target genes provided by the 
manufacturer are listed in Table 1. Target genes were labeled with FAM and housekeeping genes 
18s were labeled with VIC. The average of the CS group was used as a calibrator against which all 
other samples were expressed as fold difference. 
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Table 1: TaqMan probe sequence (Life Technology, Foster City, USA) used for real time-PCR. 
Gene name NCBI gene references FAM-labeled Probes (5’→ 3’) Assay ID 
AGRP XM_574228.2,AF206017.1 GCAGAGGTGCTAGATCCACAGAACC Rn01431703_g1 
ATGL XM_341960.3 GCCTGCCTGGGCGAAGCGGGTGCCA Rn01479969_m1 
AZGP1 NM_012826.1,D21058.1,X75309.1,BC091166.1,BC105822.1 TGGACCGAACAGATCCTCCCACTGT Rn00563201_m1 
CPT-1α NM_031559.1,L07736.1,U88294.1,BC072522.1 CCAGGAGAGTGCCAGGAGGTCATAG Rn00580702_m1 
FASN NM_017332.1,M76767.1,J03514.1,X13415.1,X62888.1 AACCTGTCCCAGGTGTGTGATGGGA Rn01645297_g1 
FOXO1 NM_001191846 AAGAGTTAGTGAGCAGGCTACATTT Rn01494868_m1 
Ob-Rb NM_012596.1 TTAATTTCCAAAAGCCTGAAACATT Rn01433205_m1 
MC4R NM_013099.2 AGCAGAAGCCTGATTCCACTGTTTA Rn01491866_s1 
NPY NM_012614.1 GCCCGCCCGCCATGATGCTAGGTAA Rn00561681_m1 
PPARγ NM_013124.2,AB019561.1,AF156666.1,Y12882.2 AGCACTTCACAAGAAATTACCATGG Rn00440940_m1 
PGC1 α NM_031347.1,AB025784.1,AY237127.1 TCTGGAACTGCAGGCCTAACTCCTC Rn00580241_m1 
POMC NM_139326.2 AAGCAACCTGCTGGCTTGCATCCGG Rn00595020_m1 
SOCS3 NM_053565.1 ACCCCCGGAGCACGCAGCCAGTGCC Rn00585674_s1 
SREBP1c XM_213329.5,AF286469.2,AF286470.2 GGGCACTGAGGCAAAGCTGAATAAA  
Rn01495769_m1 
 
Y1 receptor NM_001113357.1,Z11504.1 TTCATATGCTACTTCAAGATATACG Rn01402912_g1 
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6. Western blotting 
Proteins were isolated from the hypothalamus and quantified as previously described (Chen et al., 
2011). Proteins were separated with Novex® system (Life Tech, CA, USA) and transferred to 
polyvinylidene difluoride membranes using a transBlot semi-dry Transfer cell (Bio-Rad, Hercules, 
CA, USA). Membranes were incubated overnight at 4°C with the primary antibodies (STAT3 
(1:500), p-STAT3 (1:500), or housekeeping β-actin (1:1000), Cell Signaling Technology, Inc. 
Beverly, MA, USA), followed by secondary antibody (donkey anti-rabbit-HRP (1:10,000) for 
STAT3, goat anti-mouse, (1:5000) for p-STAT3 and β-actin), Santa Cruz Biotechnology, Dallas, 
TX, USA) for 1h at room temperature. Then the membranes were incubated with Stable Peroxide 
Solution and Enhancer Solution (Thermo Scientific, Waltham, MA, USA). Protein expression was 
detected by Universal Hood II and quantified using Quantity One software (Bio-Rad). 
 
7. Statistical Methods 
All the results in the Table and text are expressed as mean ± SEM. Those in the figures are 
presented as mean + SEM. Normality was tested and if the data were not normally distributed, they 
were log transformed prior to statistical analysis. The differences between the groups were analysed 
using a two-way ANOVA. If there was a significant interaction between the maternal and Ex-4 
effects, post hoc Bonferonni tests were performed. P<0.05 was considered significant (Statistica 8.0, 
StatSoft Inc., Tulsa, OK, USA). 
 
Results 
1. Effect of maternal obesity on the offspring  
1.1 Anthropometric characteristics 
There was no significant difference in birth weights between the offspring of the control and obese 
dams (7.07 ± 0.17g vs 6.91 ± 0.16g in offspring of control and obese dams, respectively). Maternal 
obesity led to significantly increased body weight, liver and fat mass of the offspring at P20 
(P<0.05, maternal effect, HS & HE vs CS & HE. Table 2). Body length, BMI, body and liver 
weight, as well as the percentages of liver, gonadal fat and mesenteric fat mass were significantly 
increased by maternal obesity (P<0.05, Table 2). Maternal obesity also increased liver triglyceride 
concentration (P<0.05, maternal effect, HS & HE vs CS & HE. Table 2), and plasma levels of lipids, 
including triglycerides and NEFA, but NEFA was only higher in saline-treated offspring (P<0.05, 
maternal effect, HS & HE vs CS & HE. Table 2). Plasma insulin level was also increased by 
maternal obesity (P<0.05, maternal effect, HS & HE vs CS & HE. Table 2). Plasma gut-derived 
GLP-1 levels were significantly lower, while total ghrelin levels were higher in the offspring of 
10 
  
obese dams (P<0.05, maternal effect, HS & HE vs CS & HE. Table 2). The level of the plasma 
hormone leptin was more than tripled in the offspring of obese dams compared to those from lean 
dams (P<0.05, HS vs CS. Table 2). However, blood glucose level at p10 and P20, and glucagon 
levels were not changed by maternal obesity (Table 2). 
 
Table. 2 Effects of maternal obesity and Ex-4 treatment on the body parameters at P20 
Parameters CS (n=15) CE (n=17) HS (n=11) HE (n=13) 
Body weight (g) *†δ 59.3 ± 0.5 38.8 ± 0.7† 72.8 ± 2.9* 65.1 ± 2.4*† 
Body length (cm) *†δ 12.45 ± 0.09 10.93 ± 0.11† 13.22 ± 0.17* 12.81 ± 0.16 
BMI (kg/m2) *†δ 3.81 ±0.05 3.26 ±0.08 † 4.09 ± 0.07 * 3.90 ± 0.07 
Liver (g) *†δ 2.80 ± 0.04 1.54 ± 0.04† 3.54 ± 0.17* 3.05 ± 0.15*† 
Liver (%) *†δ 4.72 ± 0.05 3.98 ± 0.04† 4.86 ± 0.07 4.60 ± 0.09* 
Retroperitoneal fat (g) *† 69.1 ± 3.2 46.2 ± 3.0 296 ± 24 241 ± 23 
Retroperitoneal fat (%) *  0.12 ± 0.01 0.11 ± 0.01 0.40 ± 0.02 0.35 ± 0.03 
Gonadal fat (g) *† 95.5 ± 4.9 69.1 ± 19.9 478 ± 42 364 ± 37 
Gonadal fat (%)*†δ 0.17 ± 0.01 0.17 ± 0.06 0.69 ± 0.04* 0.54 ± 0.04*† 
Mesenteric fat (g) *† 585 ± 20 381 ± 12 893 ± 44 724 ± 40 
Mesenteric fat (%) *†δ 0.99 ± 0.03 0.95 ± 0.02 1.26 ± 0.02* 1.10 ± 0.02*† 
Liver triglyceride 
concentration (mmol/g) *†δ 
10.2 ± 0.9 12.2 ± 1.9 42.9 ± 2.6* 30.9 ± 2.3*† 
Blood and plasma markers    
Glucose at P10 (mM) 6.20 ± 0.22 6.32 ± 0.38 6.72 ± 0.43 6.50 ± 0.33 
Glucose at P20 (mM)  7.93 ± 0.13 8.38 ± 0.16 8.25 ± 0.41 8.19 ± 0.17 
Insulin at P20 (ng/ml)* 0.76 ± 0.07 0.94 ± 0.20 1.91 ± 0.45 1.01 ± 0.20 
Triglyceride at P20 (mM) * 0.21 ± 0.03 0.24 ± 0.05 1.29 ± 0.24 1.30 ± 0.14 
NEFA at P20 (mM) *δ 0.89 ± 0.03 0.93 ± 0.06 1.35 ± 0.11* 1.06 ± 0.06† 
GLP-1 at P20 (pg/ml) 191 ± 9 182 ± 12 130 ± 15* 150 ± 9* 
Ghrelin at P20 (pg/ml) * 168 ± 28 236 ± 65 265 ± 44 410 ± 80 
Glucagon at P20 (pg/ml) 268 ± 17 360 ± 25 291 ± 68 268 ± 39 
Leptin at P20 (ng/ml) *† 2.86 ± 0.30 2.06 ± 0.10 9.60 ± 0.88 6.89 ± 0.82 
Results are expressed as mean ± S.E.M. *P<0.05, overall maternal effect; † P<0.05 overall 
Exendin-4 effect. δ P<0.05, interactions between maternal and Exendin-4 effect.* and † next to the 
numbers indicate P< 0.05 in the post hoc test. 
11 
  
1.2 Liver mRNA expression 
In pups from the obese mothers the liver insulin sensing marker PPARγ mRNA expression was 
reduced by ~50% although it did not research statistical significance (Fig 1a). Maternal obesity 
reduced some glucose and lipid metabolic markers, including liver PGC1a and fat ATGL mRNA 
expression (P<0.05, maternal effect, HS & HE vs CS & HE. Fig 1d, h); while it also significantly 
increased mRNA expression of some lipid metabolic markers, including liver SREBP1c, FASN and 
fat CPT-1α expression in P20 pups (P<0.05, maternal effect, HS & HE vs CS & HE. Fig 1b, c, g). 
Maternal obesity did not affect liver CPT-1α (Fig 1e) and FOXO1 (Fig 1f) mRNA in offspring. 
 
Figure 1. Fat metabolic markers in the liver (a-f) and retroperitoneal fat (g-i). Data are expressed as 
mean + SEM. *P<0.05, overall maternal effect; †P<0.05, overall Ex-4 effect. * and † appear 




1.3 Hypothalamic mRNA and protein expression 
In the hypothalamus, maternal obesity reduced mRNA expression of appetite-stimulating NPY, its 
receptor NPY Y1R (P<0.05, maternal effect, Fig 2b), and AGRP, as well as appetite-inhibiting 
MC4R in the offspring (P<0.05, maternal effect, Fig 2a, b, c, e). ARC appetite-inhibiting POMC 
was reduced by 35% in the saline-treated pups only. However this did not reach statistical 
significance (Fig 2d).  
 
Figure 2. mRNA expression appetite regulators in the hypothalamus at 20 days (a-g, n = 6-8) and 
protein ratio between p-STAT3 and STAT3 in the ARC at P10 (h, n = 3). Data are expressed as 
mean + SEM. *P<0.05, overall maternal effect; † P<0.05 overall Ex-4 effect. * and † appear 




The ARC leptin receptor Ob-Rb expression was not affected by maternal obesity (Fig 2f), neither 
was its downstream signaling p-STAT3/STAT3 ratio at P10 in saline injected rats. However, 
exogenous leptin injection failed to increase hypothalamic p-STAT3/STAT3 ratio or protein levels 
(data not shown) after 45 minutes. 
 
2. Effect of Ex-4 treatment on offspring  
2.1 Anthropometric characteristics 
Ex-4 treatment significantly reduced body length and BMI, especially in offspring of chow-fed 
mothers by 12% and 14% respectively (P<0.05, Ex-4 effect, CE & HE vs CS & HS; interaction 
effect between maternal obesity and Ex-4 on body length and BMI. Post hoc P<0.05, CS vs HS and 
CS vs CE, for both body length and BMI. Table 2). It also reduced body and organ weights (liver 
and fat pads) in P20 offspring regardless of the maternal group (P<0.05, Ex-4 effect, CE & HE vs 
CS & HS; interaction effect between maternal obesity and Ex-4 on body and liver weights. Post hoc 
P<0.05, CS vs HS, and CE vs HE, CS vs CE, HS vs HE, for both body and liver weights. Table 2). 
Ex-4 also reduced the percentage of liver (P<0.05, Ex-4 effects, CE & HE vs CS & HS; interaction 
effect between maternal and Ex-4. post hoc P<0.05, CE vs HE, CS vs CE), gonadal and mesenteric 
fat (P<0.05, Ex-4 effects, CE & HE vs CS & HS; interaction effect between maternal and Ex-4, 
post hoc P<0.05, CS vs HS, CE vs HE, HS vs HE, Table 2). Liver triglyceride concentration was 
significantly lower in Ex-4 treated pups (P<0.05, Ex-4 effect, CE & HE vs CS & HS; interaction 
effect between maternal and Ex-4. Post hoc P< 0.05, CS vs HS, CE vs HE, HS vs HE, Table 2). 
Blood NEFA levels were reduced by Ex-4 in offspring of obese mothers in particular (P<0.05, Ex-4 
effect, CE & HE vs CS & HS; interaction between maternal and Ex-4. Post hoc P< 0.05, HE vs HS, 
Table 2). Plasma leptin levels were also reduced by ~28% in Ex-4 treated offspring from both lean 
and obese mothers (P<0.05, Ex-4 effect, CE & HE vs CS & HS. Table 2). However, neither blood 
glucose, insulin, and triglycerides levels nor other metabolic hormones were significantly affected 
by Ex-4 treatment, although the insulin level in the HE group was nearly halved compared with the 
untreated littermates in the HS group (Table 2).   
 
2.2 Liver mRNA expression 
Liver PCG1α, CPT-1, and FOXO1 mRNA expression were upregulated by Ex-4 treatment (P<0.05, 
Ex-4 effect, CE & HE vs CS & HS. Fig 1d, e, f); whilst liver FASN and fat ATGL mRNA 
expression were decreased by Ex-4 (P<0.05, Ex-4 effect, CE & HE vs CS & HS. Fig 1c, h). There 
was a significant interaction effect between maternal obesity and Ex-4 on liver PGC1α (post hoc 
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P<0.05, CS vs CE, CE vs HE, Fig 1d) and fat ATGL (post hoc P<0.05, CS vs HS, CS vs CE, Fig 1h) 
mRNA expression, with post hoc testing indicated that Ex-4 effects were only significant in 
offspring of chow-fed mothers (P<0.05). Ex-4 also upregulated mRNA expression of AZGP1 
(P<0.05, Ex-4 effect, CE & HE vs CS & HS. Fig 1i). Although liver PPARγ mRNA expression was 
reduced by nearly 50% in both CE and HS groups compared with the CS group, there was no 
statistical significance (P<0.05, interaction effect between maternal obesity and Ex-4. Fig 1a).  
 
2.3 Hypothalamic mRNA expression 
In the hypothalamus, Ex-4 treatment increased the appetite-stimulating PVN NPY Y1R and the 
appetite-inhibiting MC4R mRNA expression, as well as the hypothalamic leptin receptor 
downstream signaling p-STAT3/STAT3 ratio at P10 (P<0.05, Fig 2b, e, h). Ex-4 treatment 
significantly reduced ARC POMC expression in the hypothalamus (P<0.05, Ex-4 effect, CE & HE 
vs CS & HS; Fig 2b, d). An interaction effect between maternal obesity and Ex-4 was observed in 
PVN NPY Y1R (post hoc P<0.05, CE vs HE, CS vs CE, Fig 2b), and ARC POMC and SOCS3 
mRNA expression (post hoc, P<0.05 CS vs CE, Fig 2d, g). 
 
Discussion  
In this study, we found that Ex-4 treatment during the suckling period led to significant reductions 
in body weight, liver mass, and fat mass of the female offspring from obese mothers. BMI and the 
percentage of liver weight were nearly normalized to the levels of the control group (CS). Ex-4 
improved markers of lipid metabolism in the liver and fat, which may have contributed to reduced 
fat mass and the improved lipid profile. Ex-4 increased hypothalamic leptin sensitivity during the 
neural developmental period in the suckling pups, leading to upregulated anorexigenic receptor 
expression.  
 
Paternal obesity may result in epigenetic modification in the offspring. However, recent human 
studies demonstrated that maternal obesity has a much stronger influence than paternal obesity not 
only on the phenotype and metabolic profile of immediate offspring (Casas et al., 2013; Patro et al., 
2013), but can also predispose the second generation to metabolic disorders (Rajia et al., 2010; 
King et al., 2013; Shasa et al., 2014). As we plan to study the second generation into the future, we 
have focused on first generation of female offspring in this study. In both human and animal studies 
maternal obesity has been shown to be strongly associated with early childhood obesity and 
metabolic disorders in both (Danielzik et al., 2002; Wu & Suzuki, 2006; Gibson et al., 2007; Chen 
et al., 2008; Chen et al., 2009). Since the BMI in childhood correlates with adult obesity (Danielzik 
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et al., 2002; Wu & Suzuki, 2006; Gibson et al., 2007), early intervention to ameliorate an obesity 
phenotype in childhood could lead to reduced chronic disease in adulthood. In this study, maternal 
obesity significantly increased the body weight and adiposity in weaning offspring, as well as their 
blood insulin and lipids levels, which is consistent with our previous observations in a similar 
model (Chen et al., 2008). These alterations were partially reversed by Ex-4 treatment during the 
critical postnatal neural developmental period. However, Ex-4 restricts the growth of the offspring 
of the lean mothers, reflected in a smaller body length and BMI, compared with the un-treated litter 
mates. The disproportionate reduced liver weight in those offspring may limit the total lipid storage 
capacity. In addition, as liver is also an important organ for glucose and lipid metabolism, in the 
offspring from the lean mothers the reduced size together with downregulated PPARγ (insulin 
sensing marker) and slight increase in insulin level (23%) suggests that early Ex-4 treatment may 
impair their glucose homeostasis which requires further long-term investigation. This growth 
restrictive effect is also consistent with the observations by Stoffers and colleagues after a six-day 
treatment from birth (Stoffers et al., 2003). This effect could be due to the appetite suppression 
effect of Ex-4 (Bojanowska & Nowak, 2007; Barrera et al., 2009; Dalvi et al., 2012). It has been 
shown that the brain response to GLP-1 can be blunted by HFD consumption (Nogueiras et al., 
2009). This could also happen in the offspring from the obese mothers as maternal obesity increases 
milk intake (Chen & Morris, 2009), and it can be speculated that the breast milk from the obese 
mothers may be richer, potentially recapitulating the effect of HFD (Gorski et al., 2006). In 
addition, the effect of Ex-4 in the offspring of the obese dams was not as pronounced as in our 
previous study focusing on post-weaning rats, where Ex-4 treated offspring did not develop HFD-
induced obesity and related metabolic disorders (Chen et al., 2014b). There are two reasons that 
may account for this difference. First, the Ex-4 dose in this study was 1/3 that of our previous study 
(15μg/kg/day), considering the young age and much smaller size of the rats. Second, immature 
homeostatic circuitry, especially in the developing hypothalamus can respond to Ex-4 differently 
from the fully developed circuitry in older rats after weaning. Indeed, the glucose lowering effect of 
Ex-4 was not significant in the weaning rats in this study, and neither blood glucose nor plasma 
glucagon was changed, suggesting a differential effect of Ex-4 in immature suckling rats. However, 
the lowered insulin level in the HE group may suggest some benefit of insulin action in maintaining 
normal blood glucose level. 
 
Hepatic biosynthesis and secretion of glucose and lipids plays a critical role in controlling blood 
glucose and lipid levels, and dysregulation of both are significant risk factors for both type 2 
diabetes and cardiovascular disease (Ginsberg, 2002; D'Adamo et al., 2010). Hyperlipidemia, liver 
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steatosis, and glucose intolerance co-exist in the offspring of obese mothers from weaning to 
adulthood (Elahi et al., 2009; Rajia et al., 2010). PPARγ is a ligand-activated transcription factor 
which is responsible for insulin sensitivity. As such, PPARγ activators such as rosiglitazone are still 
used as oral hypoglycemic drugs in patients with type 2 diabetes in some countries. Under fasting 
conditions, PPARγ expression can be increased by its upstream regulator PGC-1α to increase fatty 
acid oxidation to support energy supply (Puigserver et al., 1999; Wallberg et al., 2003). PGC-1α 
plays a key role in substrate (glucose/fatty acid) metabolism and regulating mitochondrial function 
(Finck & Kelly, 2006). In this study, reduced liver PGC-1α and a trend to a reduction in PPARγ 
expression in the offspring of the obese mothers, which may contribute to the development of 
insulin resistance (Oben et al., 2010) and result in glucose intolerance (Chen et al., 2008) as we 
have reported previously. Reduced abdominal fat mass due to Ex-4 treatment in the HE offspring 
may improve liver insulin sensitivity (Finelli & Tarantino, 2012). In addition, previously it has been 
shown that Ex-4 treatment or GLP-1 receptor antagonist can improve liver insulin sensitivity in 
both in vitro and in vivo studies (Aviv et al., 2009; Gupta et al., 2010; Lee et al., 2012). However, 
without the measurement of insulin receptor signaling cascade and insulin sensing hormone 
adiponectin, it cannot be concluded here whether liver insulin sensitivity is affected at this age 
(Finelli & Tarantino, 2013). PGC-1α activity may also increase hepatic gluconeogenesis to raise 
blood glucose level (Finck & Kelly, 2006), via its downstream signaling FOXO1 (Puigserver et al., 
2003) which was however not affected by maternal obesity. FOXO1 is normally increased by 
starvation to maintain blood glucose level (Zhou et al., 2011). In this study, FOXO1 as well as 
PGC-1α were increased by Ex-4. However blood glucose levels were not affected. As the protein 
level was not measurement, we were unable to confirm the functional relevance of upregulated 
FOXO1.  
 
The expression of several genes in the liver was changed by maternal obesity, which may be link to 
increased hepatic triglyceride concentration in such offspring here. Increased PGC-1α expression 
was shown to improve mitochondrial lipid oxidative metabolism, and inhibit the expression of 
lipogenic genes to prevent the development of hepatic steatosis (Leone et al., 2005; Finck & Kelly, 
2006). Long-term obesity has been shown to reduce PGC-1α mRNA expression and is associated 
with decreased mitochondrial lipid oxidation and increased local triglycerides accumulation 
resulting in hepatic steatosis (Petersen et al., 2003; Leone et al., 2005). Here, liver PGC-1α 
expression was downregulated by maternal obesity, which may be closely linked to the phenotype 
of liver steatosis (Bruce et al., 2009; Bayol et al., 2010; Oben et al., 2010; Caruso et al., 2011; Chen 
et al., 2014b). CPT-1α, a key downstream target of PGC-1α in lipid metabolism (Finck & Kelly, 
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2006; Liang & Ward, 2006), functions as a rate limiting step to transport fatty acid into the 
mitochondria to support ATP synthesis (Louet et al., 2002). In this study, at weaning liver CPT-1α 
mRNA level was unchanged. Normally during increased lipid influx (eg. consuming high-lipid diet) 
without an increase in lipid transportation into the mitochondria, the excess dietary fat is redirected 
for de novo lipid synthesis leading to liver steatosis, which is observed in offspring of the obese 
mothers reflected by increased liver TG concentration in this study. Excessive dietary fat influx can 
also increase liver SREBP1c mRNA expression and further FASN activation to induce lipogenesis, 
resulting in hepatic ectopic lipid accumulation (Aragno et al., 2009). In this study, SREBP1c and 
FASN was synchronically upregulated with PGC-1α, maybe linked to hyperlipidemia and increased 
liver triglyceride concentration observed in the obese offspring here. However, without the 
measurement of hepatic inflammation markers and hormones, such as IL-6, TNF-α, and adiponectin, 
the increase of which is one of the hallmarks hepatic steatosis (Tarantino et al., 2010; Finelli & 
Tarantino, 2013), we are unable to conclude whether such offspring developed hepatic steatosis.     
 
Ex-4 reduced blood NEFA level in offspring from obese mothers. This may be related to 
downregulated FASN, and upregulated PCG-1α and its downstream CPT-1α by Ex-4. In general, 
such changes have the potential to increase lipid oxidation, reduce ectopic lipid synthesis and 
accumulation in the liver. High expression of FASN signaling is closely linked to the development 
of fatty liver disease in humans (Zou et al., 2007). However, the upstream regulator of FASN, 
SREBP1c expression was unchanged, suggesting that Ex-4 may act via another unknown pathway 
to suppress FASN expression. A previous study showed that the upregulation PCG-1α mRNA can 
prevent mice from developing HFD-induced liver mitochondrial dysfunction, which is a major 
contributor to the development of fatty liver disease (Lagouge et al., 2006; Zou et al., 2014). Ex-4 
is able to ameliorate the impact of maternal obesity on PGC-1α expression. 
 
Adipose tissue is a metabolically active organ in addition to the major role it plays in energy 
storage. Fat CPT-1α mRNA was increased in the offspring of obese mothers which can be a 
response to increased fat influx into the adipocyte. However, a concurrent reduction in fat ATGL 
mRNA expression may suggest a reduced lipolysis, which can be linked to increased adiposity. 
Here we report a novel finding of the effect of Ex-4 on fat AZGP1 mRNA expression.  AZGP1 has 
been shown to stimulate lipolysis leading to fat loss in humans and mice, in conditions such as 
cigarette smoking and cancer cachexia (Vanni et al., 2009; Haugen et al., 2011; Cabassi & 
Tedeschi, 2013). AZGP1polymorphism on the other hand was shown to contribute to the onset of 
type 2 diabetes in mice (Gohda et al., 2003), while recombinant human AZGP was shown to 
18 
  
attenuate the symptoms related to type 2 diabetes in ob/ob mouse (Russell & Tisdale, 2010). In this 
study, Ex-4 significantly increased AZGP1 expression, but more so in the offspring from the lean 
dams, in the face of significantly smaller fat mass. This may be a new mechanism by which Ex-4 
causes fat loss. However, downregulated AZGP1 in the offspring of the obese mothers may be 
counteracted by downregulated ATGL expression by Ex-4 to prevent fat depletion.    
 
Maternal obesity changed both blood and brain appetite regulators. The changes in gut-derived 
hormones ghrelin and GLP-1 may directly contribute to their observed hyperphagic phenotype 
previously reported (Chen & Morris, 2009), which were not significantly affect by Ex-4 in the 
present study.  There are two major molecular forms of ghrelin, acylated ghrelin and des-acyl 
ghrelin. Recently it has been suggested that des-acyl ghrelin counteracts the orexigenic effects of 
acylated ghrelin (Stevanovic et al., 2014).  Ghrelin levels usually increase in response to fasting. 
However, somewhat paradoxically exogenous ghrelin induces more energy intake in obese 
individuals compared with lean subjects (Ariyasu et al., 2001; Druce et al., 2005; Cummings, 2006). 
Although total fasting ghrelin levels are not different between obese and lean humans, the acylated 
ghrelin levels were lower in human obese individuals (Tschop et al., 2001; Druce et al., 2005). 
Controversially, Briggs and colleagues showed that exogenous ghrelin failed to induce orexigenic 
effects in diet-induced obese rats (Briggs et al., 2010). The limitation of our ghrelin result is that 
our method did not preserve the acylated ghrelin and measured both ghrelin isoforms, so the result 
reflects total ghrelin levels. In addition, ghrelin was also measured in the non-fasting state of the 
rats. Therefore, we cannot conclude whether increased total ghrelin in offspring by maternal obesity 
in this study is linked to their hyperphagic phenotype (Chen & Morris, 2009), nor whether Ex-4 
treatment can cause hyperphagia after weaning due to increased total plasma ghrelin level. 
Additional experiments to measure acylated ghrelin in adult offspring will conducted in future 
studies. Both anorexigenic and orexigenic neurotransmitters were downregulated by maternal 
obesity potentially due to reduced neural activity as we have shown previously (Chen et al., 2014a), 
which may exert a balanced effect on feeding regulation. However, reduced anorexigenic MC4R 
and unchanged Y1R mRNA may be associated with hyperphagia as observed in our previous study 
(Chen & Morris, 2009). At P10, leptin resistance was not evident as suggested by the activation 
levels of p-STAT3/STAT3. Leptin resistance can develop in response to increased milk availability 
resulting from litter size reduction as early as P16 in mice (Glavas et al., 2010), when the leptin 
surge is finished. In this study, leptin sensitivity was measured at P10 when the major function of 
leptin is to support neural development. However, this did not normalize the appetite regulator 
expression in offspring obese mother at weaning, suggesting that other growth factors may be 
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involved in neural development during the leptin surge. The observed lack of increase in STAT3 
phosphorylation in response to exogenous leptin is also surprising and this might have been affected 
by the already elevated circulating leptin levels at P10 as previously reported (Kirk et al., 2009). 
Therefore, the dose of leptin used previously in the literature may not be sufficient to over-ride the 
effects of endogenously high leptin levels.  
 
It was interesting that Ex-4 increased leptin signaling in the hypothalamus at P10. In the HE group, 
although Ex-4 had no effect on SOCS3 (the classical inhibitor of STAT3), STAT3 activity appeared 
to be increased. Therefore, a different upstream pathway may contribute to increased leptin 
signaling activity in the obese offspring, which requires further investigation. In the short term, Ex-
4 treated offspring from lean mothers had increased both orexigenic and anorexigenic receptor 
expression, but reduced anorexigenic POMC expression; whereas offspring from obese mothers had 
an increase in anorexigenic MC4R expression. It seems that the former may support hyperphagia, 
while the latter may reduce food intake. This suggests that such an intervention using Ex-4 is only 
applicable in offspring of obese mothers, but not as prevention in those of lean mothers. Although it 
is well-known that a child’s BMI correlates with his/her own BMI in adulthood, long term follow 
up studies are needed, especially with additional environmental enrichment, such as HFD 
consumption, which is beyond the scope of this study. In addition to the short-term nature of the 
study, there are several other limitations of this paper that need to be addressed in future studies. 
Firstly, male offspring need to be examined although their direct impact to the second generation is 
not as potent as the females. Secondly, cross generational studies are of great interest to follow up 
such interventions. Thirdly, protein levels and functional studies are necessary to validate these 
findings. 
 
In summary, Ex-4 treatment during the early postnatal period showed metabolic benefit in the 
offspring of obese mothers in association with diverse effects on neurohormonal regulation of 
metabolism; whereas it caused growth restriction in those from the lean mothers.  Hence Ex-4 
should be explored in the offspring of obese mothers to limit future metabolic complications. 
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